Shots:

• Janssen is reimagining digital clinical trial design with the launch of a CHIEF-HF study. The study will evaluate Invokana (canagliflozin) vs PBO in patients aged ≥18yrs. with either preserved or reduced ejection fraction HF- with or without T2D
• The CHIEF HF study will utilize personal smartphones and wearable devices to track patient outcomes via app-based clinical questionnaires and physical activity data logged by an app on the smartphone and actigraphy data from a wearable activity device- with no in-person clinical visits required
• CHIEF-HF is the first-ever completely decentralized- mobile- indication-seeking study- design with the potential to bring faster & cost-effective therapies to the patients. The study plans to enroll ~1-900 participants in the US

Click here to­ read full press release/ article 

 Ref: Janssen | Image: Janssen